Clinical trials: Dementia Disorders
Alzheimer Disease
Activity of AVE1625 in Mild to Moderate Alzheimer's Patients.
Primary: This study is being conducted to evaluate if AVE1625 is safe and tolerated in patients with Alzheimer's disease that is not too severe.
- Trial name
- NCT00380302
- Testing
- AVE1625
- Where
- 5 sites in United States, France and 3 more
- Volunteers
- 162 people
- Sponsor
- Sanofi
Alzheimer's Disease
BPN14770 Single Ascending Dose Study in Healthy Male and Female Subjects
This is a randomized double-blind (investigator and subject blinded), placebo controlled ascending single dose study to evaluate the safety, tolerability, and pharmacokinetic profile of BPN14770 in healthy male and female…
- Trial name
- NCT02648672
- Testing
- BPN14770
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Tetra Discovery Partners
Dementia Moderate, Dementia, Mild
Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease
Xanamem® is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD).
- Conditions
- Dementia Moderate, Dementia, Mild, Alzheimer Disease
- Trial name
- XanaMIA (NCT06125951)
- Testing
- Xanamem
- Where
- 34 sites in United States, Australia
- Volunteers
- 247 people
- Sponsor
- Actinogen Medical
Alzheimer Disease
A Single Dose Escalation Study of HHT201 in Healthy Subjects
The objective of this study is to evaluate the safety and pharmacokinetic profiles of HHT201 in healthy subjects.
- Trial name
- NCT06373094
- Testing
- Donepezil Dihydroxynaphthalate for Injection
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Shanghai Synergy Pharmaceutical Sciences Co., Ltd.
Agitation
Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type
The primary objective of this study is to evaluate the efficacy of DMTS on frequency and severity of agitation associated with dementia of the Alzheimer's type, compared with placebo.
- Trial name
- NCT06052254
- Testing
- 12 cm2 - 2 Active DMTS Patches
- Where
- 8 sites in United States
- Volunteers
- 150 people
- Sponsor
- Teikoku Pharma USA, Inc.
Mild Cognitive Impairment, So Stated
Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive Impairment
The purpose of this study is to find out if different doses of Investigational Drug are safe, tolerable, and if they have an effect on Mild Cognitive Impairment (MCI).
- Trial name
- NCT00422981
- Testing
- AL-108
- Where
- 17 sites in United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Allon Therapeutics
Agitation in Patients With Dementia of the Alzheimer's Type
Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
This study was conducted to evaluate the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) compared to placebo for the treatment of agitation in participants with…
- Trial name
- NCT04464564
- Testing
- AVP-786
- Where
- 106 sites in United States, Belgium and 11 more
- Volunteers
- 241 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Alzheimers Disease
A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
The purpose of this study is to determine the effects of CNP520 on cognition, global clinical status, and underlying AD pathology, as well as the safety of CNP520, in people at risk for the onset of clinical symptoms of AD based…
- Trial name
- GS2 (NCT03131453)
- Testing
- CNP520 50mg, CNP520 15mg
- Where
- 194 sites in United States, Argentina and 23 more
- Volunteers
- 1,145 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease
A Brief Study To Evaluate The Safety, Tolerability, And Blood Levels Of Multiple Doses Of PF-044467943 Or Placebo In Combination With Donepezil In Subjects With Mild To Moderate Alzheimer's Disease
The purpose of the study is to evaluate the safety of PF-04447943 when given in combination with donepezil in subjects who have Alzheimer's Disease.
- Trial name
- NCT00988598
- Testing
- PF-04447943
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Pfizer
Alzheimer's Disease
A Safety Study of TTP4000 in Subjects With Alzheimer's Disease
The purpose of the study is to examine the safety, tolerability, immunogenicity and pharmacokinetics of TTP4000 in subjects with Alzheimer's disease with mild cognitive impairment.
- Trial name
- NCT01548430
- Testing
- TTP4000
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- vTv Therapeutics
Alzheimer's Disease
A Phase III Multi Regional Clinical Trial (MRCT) of Tricaprilin in Mild to Moderately Severe Probable Alzheimer's Disease With Optional Open Label Extension
This is Phase 3 study, multi-centre, double-blind, placebo controlled, parallel group to evaluate the effects of AC-SD-03 on the efficacy and safety among participants with mild to moderate Alzheimer's Disease.
- Trial name
- NCT04187547
- Testing
- Tricaprilin
- Sponsor
- Cerecin
Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 3
A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD
The goal of this first-in-human clinical trial is to assess the safety and tolerability of four doses of a new study drug called VO659 in people with genetic disorders called spinocerebellar ataxia type 1, type 3 or Huntington's…
- Conditions
- Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 3, Huntington Disease
- Trial name
- NCT05822908
- Testing
- VO659
- Where
- 14 sites in Denmark, France and 4 more
- Volunteers
- 68 people
- Sponsor
- Vico Therapeutics B. V.
Alzheimer's Disease (AD)
A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease
Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population.
- Trial name
- NCT05291234
- Testing
- ABBV-916
- Where
- 32 sites in United States
- Volunteers
- 106 people
- Sponsor
- AbbVie
Alzheimer's Disease, Blood Brain Barrier
Pilot Clinical Trial to Assess the Safety of NMS-01 in Patients With Mild to Moderate Alzheimer's Disease
A single-center, single-arm, prospective, open-label, pilot clinical trial to evaluate the safety and efficacy of the Focused ultrasound stimulator system (NMS-01) for transient Blood-Brain Barrier (BBB) opening in patients with…
- Trial name
- NMSBBBOYUSH01 (NCT07869238)
- Testing
- NMS-01
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Neumous Inc.
AIDS Dementia Complex, HIV Infections
A Phase III, Randomized, Double-Blind, Multicentre Study to Evaluate the Safety and Efficacy of 1592U89 in Patients With AIDS Dementia Complex
To evaluate the benefit of adding 1592U89 to current antiretroviral therapies for AIDS dementia complex and to assess the safety and tolerance of the treatment regimens.
- Trial name
- NCT00002163
- Testing
- Abacavir sulfate
- Where
- 9 sites in United States, Canada
- Sponsor
- Glaxo Wellcome
Alzheimer's Disease
A Study to Evaluate the Effect of Heat Application on the Delivery Profile of Corplex™ Donepezil Transdermal Delivery System (TDS)
A study to assess the effect of heat application on the delivery profile of Corplex™ Donepezil Transdermal Delivery System (TDS)
- Trial name
- NCT03438604
- Testing
- Donepezil TDS
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Corium, Inc.
Alzheimer's Disease
Study to Evaluate the Efficacy and Safety of GSK239512 in Alzheimer's Disease
This study aims to evaluate the cognitive enhancing effects and tolerability of GSK239512 compared to placebo in patients with mild to moderate Alzheimer's disease
- Trial name
- NCT01009255
- Testing
- GSK239512
- Where
- 35 sites in Bulgaria, Chile and 6 more
- Volunteers
- 196 people
- Sponsor
- GlaxoSmithKline
Quality of Life (QOL), Anxiety
Testing the Efficacy of the "Syd" App on Improving Quality of Life and Mental Health Among University Students in the Kingdom of Saudi Arabia
The goal of this clinical trial is to learn if using the "See Yourself Differently" (syd) app can help improve quality of life and mental health for university students in Saudi Arabia.
- Conditions
- Quality of Life (QOL), Anxiety, Stress, Affect (Mental Function)
- Trial name
- NCT06979778
- Testing
- See Yourself Differently (syd) mobile app
- Where
- Saudi Arabia
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- iamYiam Limited
Alzheimer's Disease
A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Disease
The purpose of this study is to evaluate the long-term safety and tolerability of JNJ-54861911 during 6 months of treatment in participants with early (predementia) alzheimer's disease (AD [degenerative disease of the brain…
- Trial name
- NCT02260674
- Testing
- JNJ-54861911, 10 milligram (mg), JNJ-54861911, 50 mg
- Where
- 19 sites in Belgium, France and 4 more
- Volunteers
- 114 people
- Sponsor
- Janssen Research & Development, LLC
Alzheimer's Disease
Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease
This is a global Phase III, randomized, double-blinded, placebo-controlled study for subjects with evidence of early AD. The protocol is designed to determine whether ALZT-OP1 combination treatment (ALZT-OP1a + ALZT-OP1b) will…
- Trial name
- COGNITE (NCT02547818)
- Testing
- ALZT-OP1a, ALZT-OP1b
- Where
- 121 sites in United States, Australia and 5 more
- Volunteers
- 620 people
- Sponsor
- AZTherapies, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.